Alnylam Pharmaceuticals Future Growth
Future criteria checks 6/6
Alnylam Pharmaceuticals is forecast to grow earnings and revenue by 60.6% and 20.8% per annum respectively. EPS is expected to grow by 60.1% per annum. Return on equity is forecast to be 68.8% in 3 years.
Key information
60.6%
Earnings growth rate
60.1%
EPS growth rate
Biotechs earnings growth | 20.4% |
Revenue growth rate | 20.8% |
Future return on equity | 68.8% |
Analyst coverage | Good |
Last updated | 26 Apr 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 3,079 | 257 | 673 | 778 | 21 |
12/31/2025 | 2,269 | -243 | -28 | 157 | 27 |
12/31/2024 | 1,853 | -515 | -233 | -96 | 29 |
12/31/2023 | 1,828 | -440 | 42 | 104 | N/A |
9/30/2023 | 1,724 | -510 | -67 | 2 | N/A |
6/30/2023 | 1,237 | -1,064 | -541 | -473 | N/A |
3/31/2023 | 1,143 | -1,065 | -605 | -537 | N/A |
12/31/2022 | 1,037 | -1,131 | -613 | -541 | N/A |
9/30/2022 | 961 | -1,182 | -632 | -559 | N/A |
6/30/2022 | 884 | -981 | -660 | -578 | N/A |
3/31/2022 | 880 | -893 | -654 | -577 | N/A |
12/31/2021 | 844 | -853 | -718 | -642 | N/A |
9/30/2021 | 749 | -838 | -691 | -615 | N/A |
6/30/2021 | 688 | -887 | -653 | -591 | N/A |
3/31/2021 | 571 | -876 | -672 | -604 | N/A |
12/31/2020 | 493 | -858 | -685 | -615 | N/A |
9/30/2020 | 401 | -891 | -775 | -688 | N/A |
6/30/2020 | 345 | -846 | -871 | -760 | N/A |
3/31/2020 | 286 | -886 | -452 | -336 | N/A |
12/31/2019 | 220 | -886 | -419 | -278 | N/A |
9/30/2019 | 169 | -821 | -372 | -233 | N/A |
6/30/2019 | 101 | -858 | -352 | -204 | N/A |
3/31/2019 | 86 | -802 | -745 | -595 | N/A |
12/31/2018 | 75 | -761 | -690 | -563 | N/A |
9/30/2018 | 92 | -692 | -625 | -515 | N/A |
6/30/2018 | 107 | -570 | -550 | -460 | N/A |
3/31/2018 | 93 | -525 | -527 | -438 | N/A |
12/31/2017 | 90 | -491 | -487 | -383 | N/A |
9/30/2017 | 69 | -462 | N/A | -358 | N/A |
6/30/2017 | 66 | -443 | N/A | -335 | N/A |
3/31/2017 | 59 | -414 | N/A | -324 | N/A |
12/31/2016 | 47 | -410 | N/A | -308 | N/A |
9/30/2016 | 37 | -388 | N/A | -282 | N/A |
6/30/2016 | 30 | -361 | N/A | -261 | N/A |
3/31/2016 | 30 | -342 | N/A | -247 | N/A |
12/31/2015 | 41 | -290 | N/A | -189 | N/A |
9/30/2015 | 58 | -221 | N/A | -173 | N/A |
6/30/2015 | 62 | -188 | N/A | -159 | N/A |
3/31/2015 | 61 | -160 | N/A | -150 | N/A |
12/31/2014 | 51 | -360 | N/A | -166 | N/A |
9/30/2014 | 37 | -371 | N/A | -151 | N/A |
6/30/2014 | 35 | -357 | N/A | -132 | N/A |
3/31/2014 | 37 | -331 | N/A | -109 | N/A |
12/31/2013 | 47 | -89 | N/A | -69 | N/A |
9/30/2013 | 45 | -119 | N/A | -115 | N/A |
6/30/2013 | 53 | -109 | N/A | -88 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 0HD2 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.6%).
Earnings vs Market: 0HD2 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 0HD2 is expected to become profitable in the next 3 years.
Revenue vs Market: 0HD2's revenue (20.8% per year) is forecast to grow faster than the UK market (3.4% per year).
High Growth Revenue: 0HD2's revenue (20.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 0HD2's Return on Equity is forecast to be very high in 3 years time (68.8%).